Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial.
Nat Commun
; 14(1): 5914, 2023 09 22.
Article
in En
| MEDLINE
| ID: mdl-37739939
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Multiomics
/
Melanoma
Type of study:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
Nat Commun
Journal subject:
BIOLOGIA
/
CIENCIA
Year:
2023
Document type:
Article
Affiliation country:
Country of publication: